3.625
3.63 (-2.77%)
As of Mar 06, 2024
Inventiva S.A. [IVA]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing lanifibranor for the treatment of NASH, as well as a pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need.
Country | France |
Headquarters | daix |
Phone Number | 33380447500 |
Industry | |
CEO | Frã©Dã©Ric Cren |
Website | inventivapharma.com |